ZA200708222B - A host cell comprising a vector for production of proteins requiring gamma-carboxylation - Google Patents

A host cell comprising a vector for production of proteins requiring gamma-carboxylation

Info

Publication number
ZA200708222B
ZA200708222B ZA200708222A ZA200708222A ZA200708222B ZA 200708222 B ZA200708222 B ZA 200708222B ZA 200708222 A ZA200708222 A ZA 200708222A ZA 200708222 A ZA200708222 A ZA 200708222A ZA 200708222 B ZA200708222 B ZA 200708222B
Authority
ZA
South Africa
Prior art keywords
carboxylation
vector
production
host cell
requiring gamma
Prior art date
Application number
ZA200708222A
Other languages
English (en)
Inventor
Loevgren Ann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200708222B publication Critical patent/ZA200708222B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
ZA200708222A 2005-04-13 2007-09-26 A host cell comprising a vector for production of proteins requiring gamma-carboxylation ZA200708222B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500831 2005-04-13

Publications (1)

Publication Number Publication Date
ZA200708222B true ZA200708222B (en) 2008-11-26

Family

ID=37087286

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708222A ZA200708222B (en) 2005-04-13 2007-09-26 A host cell comprising a vector for production of proteins requiring gamma-carboxylation

Country Status (17)

Country Link
US (3) US7989193B2 (xx)
EP (1) EP1874928A1 (xx)
JP (1) JP5461008B2 (xx)
KR (2) KR101599062B1 (xx)
CN (1) CN101198696B (xx)
AR (1) AR053053A1 (xx)
AU (1) AU2006234788B2 (xx)
BR (1) BRPI0609120A2 (xx)
CA (1) CA2602793C (xx)
IL (1) IL186036A0 (xx)
MX (1) MX2007012704A (xx)
NO (1) NO20075088L (xx)
NZ (1) NZ561925A (xx)
RU (1) RU2415934C2 (xx)
TW (1) TWI384070B (xx)
WO (1) WO2006110083A1 (xx)
ZA (1) ZA200708222B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2453895T3 (es) 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Células que expresan vitamina K epóxido reductasa y uso de las mismas
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
CA2632794C (en) * 2005-12-02 2015-04-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
ES2503365T5 (es) * 2005-12-21 2017-10-31 Cnj Holdings, Inc Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
WO2009100040A2 (en) * 2008-02-01 2009-08-13 Chromocell Corporation Cell lines expressing gabaa and methods using them
CA2751215A1 (en) * 2009-02-02 2010-08-05 Chromocell Corporation Cell lines expressing cftr and methods of using them
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
EP2816108A1 (en) * 2013-06-21 2014-12-24 Baxter International Inc Transformed fungus with vitamin K dependent activity
CN104293737B (zh) * 2014-09-16 2017-06-13 太原博奥特生物技术有限公司 一种包含表达功能性重组人凝血因子ⅶ载体的宿主细胞及其高水平表达方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN111154725A (zh) * 2020-01-20 2020-05-15 河南科技大学 一种用于筛选维生素k循环小分子抑制剂的双报告基因细胞体系、制备方法及其应用
CN111239386B (zh) * 2020-01-20 2023-03-14 河南科技大学 一种靶向抑制维生素K依赖性γ-谷氨酰羧化酶的小分子化合物的筛选方法及应用
KR20230004002A (ko) * 2021-06-30 2023-01-06 씨제이제일제당 (주) 고농도 l-글루탐산을 생산하기 위한 균주 및 이를 이용한 l-글루탐산 생산방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
AU8427091A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Gamma-carboxylase and methods of use
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
CZ81997A3 (en) 1996-03-20 1997-10-15 Immuno Ag Pharmaceutical preparation for treating disorders connected with blood clotting, process of its preparation and use
AU2015799A (en) 1997-12-24 1999-07-19 Immunex Corporation V201 dna and polypeptides
EP1196610A2 (en) 1999-07-09 2002-04-17 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
WO2001007068A1 (en) 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
BR0114374A (pt) * 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
ATE423199T1 (de) 2001-07-06 2009-03-15 Chemo Sero Therapeut Res Inst Verfahren zur herstelllung von menschlichem thrombin mittels genmodifikationstechnik
EP1405912B8 (en) 2001-07-06 2012-10-24 The Chemo-Sero-Therapeutic Research Institute Genetically modified ecarin and process for producing the same
EP1407780B1 (en) 2001-07-10 2013-05-01 The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
ES2453895T3 (es) * 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Células que expresan vitamina K epóxido reductasa y uso de las mismas
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1673450B1 (en) 2003-10-14 2010-04-28 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US7829306B2 (en) 2003-10-24 2010-11-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Protein highly producing recombinant animal cell, method for preparing the same, and method for mass-producing protein using the same
JP2008523837A (ja) 2004-12-21 2008-07-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ガンマ―カルボキシル化に欠陥のある宿主系におけるガンマ―カルボキシル化ポリペプチドの発現
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
CA2632794C (en) 2005-12-02 2015-04-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
ES2503365T5 (es) 2005-12-21 2017-10-31 Cnj Holdings, Inc Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
AU2006234788A1 (en) 2006-10-19
RU2415934C2 (ru) 2011-04-10
US20130065295A1 (en) 2013-03-14
JP2008535517A (ja) 2008-09-04
IL186036A0 (en) 2008-02-09
CN101198696A (zh) 2008-06-11
EP1874928A1 (en) 2008-01-09
JP5461008B2 (ja) 2014-04-02
US20080312127A1 (en) 2008-12-18
CA2602793C (en) 2016-11-22
NZ561925A (en) 2010-04-30
US8304224B2 (en) 2012-11-06
AU2006234788B2 (en) 2011-07-14
AR053053A1 (es) 2007-04-18
KR20080002949A (ko) 2008-01-04
NO20075088L (no) 2007-11-12
TW200716753A (en) 2007-05-01
RU2007140550A (ru) 2009-05-20
WO2006110083A1 (en) 2006-10-19
US7989193B2 (en) 2011-08-02
KR20130140221A (ko) 2013-12-23
TWI384070B (zh) 2013-02-01
BRPI0609120A2 (pt) 2010-11-16
CN101198696B (zh) 2014-02-26
MX2007012704A (es) 2008-01-14
US20120077229A1 (en) 2012-03-29
CA2602793A1 (en) 2006-10-19
KR101599062B1 (ko) 2016-03-02

Similar Documents

Publication Publication Date Title
ZA200708222B (en) A host cell comprising a vector for production of proteins requiring gamma-carboxylation
HK1124488A1 (en) Production of canola protein
EP1937313A4 (en) HOST CELL LINES USEFUL IN THE PRODUCTION OF A CONSTANT ANTIBODY REGION HAVING IMPROVED FUNCTIONING FUNCTION
IL190731A0 (en) Production of oligodendrocytes from placenta-derived stem cells
EP1899476A4 (en) CELLULASE PRODUCTION
IL190550A0 (en) Methods of protein production using anti-senescence compounds
EP1969123A4 (en) NEW ENZYMES
EG26462A (en) Polypeptide production
EP1861408A4 (en) PROCESS FOR PRODUCING HYDROCHLOROSILANES
GB0505064D0 (en) Production of bio-diesel
EP1874948A4 (en) PROCESS FOR THE PREPARATION OF Y-GLUTAMYLCYSTEIN
EP1870452A4 (en) PROCESS FOR PRODUCING REGULATORY T CELL
IL172037A (en) Letrozole production process
GB0426160D0 (en) Production of proteins
EP2019860A4 (en) PROTEIN PRODUCTION USING EUKARYOTIC CELL LINES
GB2432583B (en) Letrozole production process
IL187155A0 (en) Process for production of 4-biphenylazetidin-2-ones
IL189101A0 (en) Novel processes for the production of amorphous rabeprazole sodium
IL189739A0 (en) System for screening cells for high expression of a protein
EP1885868A4 (en) PREPARATION OF ENZYMES
ZA200710066B (en) Process for production of 4-biphenylylazetidin-2-ones
EP1889824A4 (en) PROCESS FOR PRODUCING STYRENE
EP1917231A4 (en) PROCESS FOR THE PREPARATION OF BROMOPICRIN
IL165484A0 (en) Production of proteins
IL184221A0 (en) Process for the manufacture of taurine